Evidence map›Paper›PMID 27238723›Full record

ArticleChemico-biological interactions2016

Paraoxonases-1, -2 and -3: What are their functions?

Clement E Furlong, Judit Marsillach, Gail P Jarvik, Lucio G Costa

Abstract read
In one paragraph

Article in Chemico-biological interactions, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 2 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 2 syntheses or guidelines pooled it, 200 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. The Paraoxonase (International journal of molecular sciences · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Clement E FurlongDepartments of Medicine (Division of Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA, USA. Electronic address: clem@uw.edu.
Judit MarsillachDepartments of Medicine (Division of Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA, USA. Electronic address: jmarsi@uw.edu.
Gail P JarvikDepartments of Medicine (Division of Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA, USA. Electronic address: pair@uw.edu.
Lucio G CostaDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA; Department of Neuroscience, University of Parma, Parma, Italy. Electronic address: lgcosta@uw.edu.
University of Washington Medical Center · USUniversity of Washington · US

Funding

WILDLIFE BIOMARKER APPLICATIONS TO REMEDIATION DECISION MAKINGP42ES004696 · NIEHS · UNIVERSITY OF WASHINGTON · PI FURLONG, CLEMENT EUGENE · 1987 to 2021
$51.2M
XENOBIOTIC BIOTRANSFORMATION AND DISPOSITIONP30ES007033 · NIEHS · UNIVERSITY OF WASHINGTON · PI Sheela Sathyanarayana · 1995 to 2026
$42.5M
Variation, Function, and Disease Supplement ProgramU01HG008657 · NHGRI · UNIVERSITY OF WASHINGTON · PI David Russell Crosslin, Gail Pairitz Jarvik · 2015 to 2026
$13.4M
STUDY OF CELLULAR &MOLECULAR ASPECTS OF PESTICIDE NEURODEVELOPMENTAL TOXICITYP01ES009601 · NIEHS · UNIVERSITY OF WASHINGTON · PI THOMPSON, ENGELBERTA · 1999 to 2013
$8.7M
Pacific Northwest Agricultural Safety and Health CenterU50OH007544 · OH · UNIVERSITY OF WASHINGTON · PI FENSKE, RICHARD ARNOLD · 2001 to 2010
$7.1M
STRUCTURE/FUNCTION OF THE HUMAN PON1 POLYMORPHISMR01ES009883 · NIEHS · UNIVERSITY OF WASHINGTON · PI FURLONG, CLEMENT EUGENE · 1999 to 2013
$5.3M
Prediction and Progression of Carotid Artery DiseaseR01HL067406 · NHLBI · UNIVERSITY OF WASHINGTON · PI JARVIK, GAIL PAIRITZ · 2002 to 2009
$5.1M
NHGRI NIH HHS U01 HG008657NHLBI NIH HHS R01 HL067406NIEHS NIH HHS P01 ES009601NIEHS NIH HHS P30 ES007033NIEHS NIH HHS P42 ES004696NIEHS NIH HHS R01 ES009883NIOSH CDC HHS U50 OH007544
6 · The paper itself

Abstract

Paraoxonase-1 (PON1), an esterase/lactonase primarily associated with plasma high-density lipoprotein (HDL), was the first member of this family of enzymes to be characterized. Its name was derived from its ability to hydrolyze paraoxon, the toxic metabolite of the insecticide parathion. Related enzymes PON2 and PON3 were named from their evolutionary relationship with PON1. Mice with each PON gene knocked out were generated at UCLA and have been key for elucidating their roles in organophosphorus (OP) metabolism, cardiovascular disease, innate immunity, obesity, and cancer. PON1 status, determined with two-substrate analyses, reveals an individual's functional Q192R genotype and activity levels. The three-dimensional structure for a chimeric PON1 has been useful for understanding the structural properties of PON1 and for engineering PON1 as a catalytic scavenger of OP compounds. All three PONs hydrolyze microbial N-acyl homoserine lactone quorum sensing factors, quenching Pseudomonas aeruginosa's pathogenesis. All three PONs modulate oxidative stress and inflammation. PON2 is localized in the mitochondria and endoplasmic reticulum. PON2 has potent antioxidant properties and is found at 3- to 4-fold higher levels in females than males, providing increased protection against oxidative stress, as observed in primary cultures of neurons and astrocytes from female mice compared with male mice. The higher levels of PON2 in females may explain the lower frequency of neurological and cardiovascular diseases in females and the ability to identify males but not females with Parkinson's disease using a special PON1 status assay. Less is known about PON3; however, recent experiments with PON3 knockout mice show them to be susceptible to obesity, gallstone formation and atherosclerosis. Like PONs 1 and 2, PON3 also appears to modulate oxidative stress. It is localized in the endoplasmic reticulum, mitochondria and on HDL. Both PON2 and PON3 are upregulated in cancer, favoring tumor progression through mitochondrial protection against oxidative stress and apoptosis.

Indexed as

AnimalsAryldialkylphosphataseAstrocytesCarotid Artery DiseasesCells, CulturedClopidogrelEndoplasmic ReticulumFemaleGenotypeHomocysteineHumansInflammationLipid MetabolismLipoproteins, HDLMaleMiceAryldialkylphosphataseClopidogrelHomocysteinehomocysteine thiolactoneLipoproteins, HDLOrganophosphorus CompoundsPlatelet Aggregation InhibitorsPON3 protein, mouseTiclopidineAnti-inflammatoryHuman diseaseOrganophosphateOxidative stressParaoxonases

Identifiers

PMID27238723
PMCPMC5391248
OpenAlexW2405907603

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.